ppGpp is a bacterial cell size regulator.

Curr Biol

Department of Bionanoscience, Kavli Institute of Nanoscience, Delft University of Technology, Delft, the Netherlands; AMOLF, Amsterdam, the Netherlands. Electronic address:

Published: February 2022

Growth and division are central to cell size. Bacteria achieve size homeostasis by dividing when growth has added a constant size since birth, termed the adder principle, by unknown mechanisms. Growth is well known to be regulated by guanosine tetraphosphate (ppGpp), which controls diverse processes from ribosome production to metabolic enzyme activity and replication initiation and whose absence or excess can induce stress, filamentation, and small growth-arrested cells. These observations raise unresolved questions about the relation between ppGpp and size homeostasis mechanisms during normal exponential growth. Here, to untangle effects of ppGpp and nutrients, we gained control of cellular ppGpp by inducing the synthesis and hydrolysis enzymes RelA and Mesh1. We found that ppGpp not only exerts control over the growth rate but also over cell division and thus the steady state cell size. In response to changes in ppGpp level, the added size already establishes its new constant value while the growth rate still adjusts, aided by accelerated or delayed divisions. Moreover, the magnitude of the added size and resulting steady-state birth size correlate consistently with the ppGpp level, rather than with the growth rate, which results in cells of different size that grow equally fast. Our findings suggest that ppGpp serves as a key regulator that coordinates cell size and growth control.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cub.2021.12.033DOI Listing

Publication Analysis

Top Keywords

cell size
16
growth rate
12
size
11
ppgpp
9
growth
8
size homeostasis
8
ppgpp level
8
cell
5
ppgpp bacterial
4
bacterial cell
4

Similar Publications

Background: Our previous study identified that Sildenafil (a phosphodiesterase type 5 [PDE5] inhibitor) is a candidate repurposable drug for Alzheimer's Disease (AD) using in silico network medicine approach. However, the clinically meaningful size and mechanism-of-actions of sildenafil in potential prevention and treatment of AD remind unknown.

Method: We conducted new patient data analyses using both the MarketScan® Medicare with Supplemental database (n = 7.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Longeveron Inc., Miami, FL, USA.

Background: Alzheimer's disease (AD) is characterized by progressive atrophy of the cerebral cortex and hippocampus, with concomitant increase in ventricular volume. Lomecel-B is a novel cell-based therapeutic approach to AD that targets neuroinflammation, microvascular dysfunction, and has the potential to stimulate endogenous tissue regeneration. We conducted MRI analysis of brain morphology in the CLEAR-MIND study, a 49-patient proof-of-concept study that tested 3 different dosing regimens of Lomecel-B vs placebo in patients with mild AD dementia.

View Article and Find Full Text PDF

Background: Homozygosity for the rare APOE3-Christchurch (APOE3Ch) variant, encoding for apoE3-R136S (apoE3-Ch), was linked to resistance against an aggressive form of familial Alzheimer's disease (AD). Carrying two copies of APOE3Ch was sufficient to delay autosomal AD onset by 30 years. This remarkable protective effect makes it a strong candidate for uncovering new therapies against AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Longeveron Inc., Miami, FL, USA.

Background: Lomecel-B is a novel cell-based therapy with potential to demonstrate clinical benefit on Alzheimer's disease (AD) and its progression. Here we present the results of a phase 2a proof-of-concept trial (n = 49) to further define the potential of Lomecel-B in patients with mild AD dementia.

Methods: This double-blind, randomized, placebo-controlled 45-week trial (ClinicalTrials.

View Article and Find Full Text PDF

Introduction: Taohong Siwu decoction (THSWD), a traditional prescription for enhancing blood circulation and eliminating blood stasis, primarily comprises peach kernel, safflower, angelica, chuanxiong, and rehmannia. Modified Taohong Siwu decoction (MTHSWD), an advanced version of THSWD, incorporates additional ingredients such as epimedium, cinnamon, and salvia miltiorrhiza. This addition serves to augment its efficacy in warming yang and promoting blood circulation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!